Selective transcription of p53 target genes by zinc finger-p53 DNA binding domain chimeras

被引:5
作者
Falke, D [1 ]
Fisher, MH [1 ]
Juliano, RL [1 ]
机构
[1] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION | 2004年 / 1681卷 / 01期
关键词
transcription; zinc finger; P53; P21; DNA-binding;
D O I
10.1016/j.bbaexp.2004.09.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Active p53 stimulates the transcription of a number of key genes, including the pro-apoptotic gene bax, as well as p21, a cell cycle regulator. In this study we constructed novel chimeric zinc finger-p53 DNA binding domain (DBD) transcription factors designed to bind to the promoters of specific p53 regulated genes. In order to selectively increase the expression of Bax, we coupled a pre-selected three-zinc finger (Zif) peptide targeted to a sequence in the bax promoter to a minimal p53 DBD. This chimeric protein could increase reporter gene transcription from a minimal bax promoter (up to 10-fold) but not from a minimal p21 promoter in p53-deficient Saos-2 cells. However, fusion proteins carrying longer p53 DBDs displayed entirely different selectivity and potency. Thus, Zif-p53 DBD chimeras containing Nand C-terminal extensions of the minimal DBD could increase transcription driven by a minimal p21 promoter up to 800-fold. These chimeras preferred the minimal p21 promoter up to 500-fold over the minimal bax promoter. Additionally, endogenous p21 message and protein levels were increased in cells expressing the p21 selective Zif-p53 DBD chimera and expression of the chimeric proteins resulted in partial cell cycle arrest. Cell fractionation experiments indicated that the Zifs enhanced nuclear localization of the Zif-p53 DBD chimera. These studies suggest that it is possible to create chimeric transcription factors able to strongly and selectively activate genes downstream of p53. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:15 / 27
页数:13
相关论文
共 47 条
[21]   Strategies for manipulating the p53 pathway in the treatment of human cancer [J].
Hupp, TR ;
Lane, DP ;
Ball, KL .
BIOCHEMICAL JOURNAL, 2000, 352 :1-17
[22]   Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence [J].
Inga, A ;
Storici, F ;
Darden, TA ;
Resnick, MA .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (24) :8612-8625
[23]   Influence of promoter DNA topology on sequence-specific DNA binding and transactivation by tumor suppressor p53 [J].
Kim, E ;
Rohaly, G ;
Heinrichs, S ;
Gimnopoulos, D ;
Meissner, H ;
Deppert, W .
ONCOGENE, 1999, 18 (51) :7310-7318
[24]   Design of TATA box-binding protein zinc finger fusions for targeted regulation of gene expression [J].
Kim, JS ;
Kim, J ;
Cepek, KL ;
Sharp, PA ;
Pabo, CO .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) :3616-3620
[25]   p53: Puzzle and paradigm [J].
Ko, LJ ;
Prives, C .
GENES & DEVELOPMENT, 1996, 10 (09) :1054-1072
[26]   Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function [J].
Kong, XT ;
Gao, HX ;
Stanbridge, EJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (35) :32990-33000
[27]   Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21WAF1/Cip1 gene by the p53 tumor suppressor protein [J].
Koutsodontis, G ;
Tentes, I ;
Papakosta, P ;
Moustakas, A ;
Kardassis, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (31) :29116-29125
[28]   p53, the cellular gatekeeper for growth and division [J].
Levine, AJ .
CELL, 1997, 88 (03) :323-331
[29]  
Ludwig RL, 1996, MOL CELL BIOL, V16, P4952
[30]  
MIYASHITA T, 1995, CELL, V80, P293